MIRM (Mirum Pharmaceuticals, Inc.) רווח למניה בשנים עשר החודשים האחרונים

The success of Mirum Pharmaceuticals (MIRM) depends on the commercial advancement of Livmarli and the expansion of its approved indications. The year-over-year change in EPS (TTM) demonstrates the pace of overcoming operational stagnation, where the value of -1678.50 reflects this status. Revenues are based on the therapy of rare liver pathologies, while the growth strategy relies on the targeted acquisition of new rights to refresh the drug portfolio.
mirumpharma.com - פילוחים אנליטיים ומדדי מפתח (MIRM)

Mirum Pharmaceuticals (MIRM) is scaling sales of revolutionary drugs for the therapy of rare pediatric liver pathologies, saving patients' lives. Analyzing this chart of the annual percentage growth of EPS TTM, an investor can see the earnings per share dynamics over twelve months, where high volatility signals business instability and low values warn of the risk of a value trap.